Rockefeller Capital Management
CBAY

Rockefeller Capital Management’s Cymabay Therapeutics CBAY Stock Holding History

Rockefeller Capital Management’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,000
Closed -$156K – 4073
2022
Q4 		$156K Sell
25,000
-189,200
-88% -$719K ﹤0.01% 1790
2022
Q3 		$749K Hold
214,200
– – ﹤0.01% 1117
2022
Q2 		$631K Sell
214,200
-13,175
-6% -$31.5K ﹤0.01% 1174
2022
Q1 		$707K Buy
227,375
+525
+0.2% +$1.65K ﹤0.01% 1186
2021
Q4 		$766K Buy
226,850
+102,850
+83% +$390K ﹤0.01% 1151
2021
Q3 		$452K Buy
124,000
+25,000
+25% +$98.5K ﹤0.01% 1302
2021
Q2 		$431K Buy
+99,000
New +$439K ﹤0.01% 1252

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PA
Perceptive Advisors New York $5.06B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return